Literature DB >> 11707739

Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates.

M Deschênes1, R P Michel, E Alpert, J S Barkun, P Metrakos, J Tchervenkov.   

Abstract

BACKGROUND: CA (cancer antigen) 125 is a serologic marker used in the monitoring of ovarian cancer. Elevated levels are also reported in cirrhosis. We evaluated the range of serum CA 125 levels seen before and after liver transplantation, and examined possible factors associated with CA 125 elevation.
METHODS: We examined prospectively 57 consecutive patients with cirrhosis who underwent liver transplantation. CA 125 levels were also measured in two patients with polycystic liver disease.
RESULTS: The mean serum CA 125 level before transplantation was 352+/-549 u/ml, compared with 46+/-49 u/ml after transplantation (P<0.001). Multivariate analysis identified the degree of ascites as the only significant predictive variable of preoperative CA 125 level. In five patients who underwent abdominal paracentesis, the mean ascites CA 125 level (951+/-322 u/ml) was higher than that of the serum (619+/-290 u/ml) (P<0.003). In 16 hepatectomy specimens, the grade of staining for CA 125 was 0.8+/-1.4 for the mesothelium of patients with a normal serum CA 125 level, compared with 1.5+/-1.1 in patients with elevated serum levels (P=0.37). Two patients with severe abdominal distension due to polycystic liver disease but without ascites had elevated serum CA 125 levels. DISCUSSION: CA 125 concentration is elevated in the majority of patients with cirrhosis and normalizes after liver transplantation. It is a reflection of the abdominal distention seen in these patients. Therefore, an elevation in CA 125 should not be considered a contraindication to liver transplantation in the absence of evidence of malignancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707739     DOI: 10.1097/00007890-200111150-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Marked decrease of serum Ca 125 levels after Denver shunt placement in a patient with cirrhosis and refractory ascites.

Authors:  L Leggio; L Abenavoli; C D'Angelo; A Ferrulli; L Vonghia; A Mirijello; R Barbarino; T De Michele; C Zuppi; D Gui; G L Rapaccini; G Gasbarrini; G Addolorato
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 2.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 3.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

4.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.